Pre-Clinical CRO

Pre-Clinical CRO

Products

Information

- Transient protein production CHO (& HEK) from proprietary QMCF expression platform - Hundreds of protein candidates in parallel - From mgs to grams, from ml’s to dozens of liters scale (chemically defined, serum-free medium) - Protein for in-vitro and in-vivo purposes - Automated, high-throughput platform purifications till in-depth multi-step downstream processes - Latest & broad analytical capabilities, incl. high-throughput platforms: Biochemical, biophysical & cell-based potency assays - ADCC enhancement platform, for afucosylated mAbs - Pre-clinical ADC capabilities, expression, conjugation, purification, analytics - The goal is to analyze candidate molecules for their critical characteristics (manufacturability, stability, activity, potency), to select a few lead candidates, further optimize them as needed and proceed straight into clinical development, without any CRO to CDMO tech transfer
IcosagenIcosagen is a private, independent family-business, advancing therapeutic proteins from mammalian cells since 26 years. As CRDMO, we uniquely combine pre-clinical CRO and clinical CDMO capabilities at one site, advancing molecules from discovery through R&D stages, into stable IcoCell(R) CHO cell lines and GMP manufacturing. From mAbs, complex multi-specifics to ADCs or recombinant proteins, we accelerate the programs of over 100 biotechs annually, eliminating error-prone tech transfers to save our partners' time, cost and effort.

Log in

See all the content and easy-to-use features by logging in or registering!